Company: ATRA
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059322
Chunk: 46

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 46
---
 to 500 employees

Geography — U.S.-based companies located in biotechnology “hub” locations

<div align='center'>29</div>

Following this analysis, the Human Capital Committee identified the following 18 publicly-traded, U.S-based biotechnology/pharmaceutical companies as our peer group to be used in reviewing compensation for 2024:

| Peer Group used to determine 2024 Compensation |                             |                               |
| Actinium Pharmaceuticals Inc.*                 | Agenus Inc.                 | Alector Inc.                  |
| Allogene Therapeutics Inc.                     | Allo Vir Inc.               | Bluebird bio, Inc.            |
| Fate Therapeutics, Inc.                        | Instil Bio, Inc.            | Iovance Biotherapeutics, Inc. |
| Karyopharm Therapeutics Inc.                   | Kronos Bio, Inc.            | MacroGenics, Inc.             |
| Nkarta, Inc.                                   | Nurix Therapeutics, Inc.    | Poseida Therapeutics, Inc.    |
| Precision Biosciences, Inc.                    | Rigel Pharmaceuticals, Inc. | Y-mAbs Therapeutics Inc.*     |

* Indicates new peer for 2024 compensation decisions; Clovis Oncology, Inc., ImmunoGen, Inc., TCR2 Therapeutics Inc., and TG Therapeutics Inc. were removed from peer group for 2024 compensation decisions as each fell outside of the peer selection criteria described above. Elements of Executive Compensation The Human Capital Committee has developed an executive compensation program that consists of the following primary elements: • Base salary; • Short-term incentives in the form of an annual cash bonus opportunity; and • Long-term incentives in the form of equity-based compensation (restricted stock units (“RSUs”)). The relative mix of these components is generally weighted towards incentive rather than fixed compensation and towards long-term incentive compared to short-term incentive compensation. We believe this relative weighting towards long-term equity-based compensation further aligns the interests of our executive officers with those of our stockholders.

| Base Salary                 | Base salaries are set to be competitive within our industry and are important in attracting and retaining talented executives. Base salaries are fixed pay set with consideration for responsibilities, market data, employee knowledge, skills and experience, individual performance and scope of responsibilities, among other factors.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Annual Cash Bonus           | The annual cash incentive award plan is intended to motivate and reward our executives for the achievement of individual goals as well as the strategic goals of the Company